Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients

BACKGROUND: Imatinib is used to treat chronic myelogenous leukemia (CML). Variations in imatinib pharmacokinetics have been linked to genetic variations. That has an impact on imatinib response and adverse effects. Therefore, the aim of the study was to study bone pain as an adverse effect that occu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamza, Marwa S, Shouman, Samia A, Abdelfattah, Raafat, Moussa, Heba S, Omran, Mervat M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166450/
https://www.ncbi.nlm.nih.gov/pubmed/35669281
http://dx.doi.org/10.2147/DDDT.S365646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166450/
https://www.ncbi.nlm.nih.gov/pubmed/35669281
http://dx.doi.org/10.2147/DDDT.S365646

Ejemplares similares